2X1:ETR
Abivax SA
€ 83,55
arrow_downward
-0,71%(-0,60) 1D
2 de out., 17:35:35 GMT+2 · EUR
search
Todos os ativos
| Códigos | Preço | Variação | % de variação |
|---|
insights_autoGerando os principais insights para 2X1…
Abrir
€ 83,15
Alta
€ 84,50
Baixa
€ 83,00
Valor de mercado
7,20 bi
Volume médio
1,78 mil
Volume
842,00
Alto — 52 sem
€ 137,40
Baixo — 52 sem
€ 60,85
LPA
-€ 5,20
Nº de funcionários
98
Abrir
€ 83,15
Alta
€ 84,50
Baixa
€ 83,00
Valor de mercado
7,20 bi
Volume médio
1,78 mil
Volume
842,00
Alto — 52 sem
€ 137,40
Baixo — 52 sem
€ 60,85
LPA
-€ 5,20
Nº de funcionários
98
Notícias
De fontes da web e parceiros de notícias
MarketBeat
·
há 3 dias
Abivax (NASDAQ:ABVX) Stock Price Down 5.1% - Should You Sell?
Perfil
Abivax SA is a clinical stage biotechnology company focused on developing innovative treatments that harness the body’s natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases.
Abivax has a program in clinical development with its lead drug candidate, obefazimod, to treat ulcerative colitis. Another program in Crohn’s disease is also in preparation and other potential inflammatory indications are being evaluated.
The company’s headquarters are based in Paris, France with a US office in Waltham, Massachusetts. Abivax’s Research and development work is conducted at its research center based in Montpellier, France. Wikipedia
Sobre Abivax SA
CEOMarc de Garidel | Hartmut J. Ehrlich
Funcionários98
Data de fundação4 de dez. de 2013
Sede-
Setor-
Siteabivax.com